Addex stops migraine study after liver abnormalities

Addex Pharmaceuticals Ltd. (SIX:ADXN) discontinued the Phase IIb ADX10059-206 trial of ADX10059 to prevent migraine after routine safety monitoring of blinded data showed a higher than expected incide...